Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
/in International Publications, Newcastle Disease Virus /von 2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-38A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization
/in International Publications, Newcastle Disease Virus /von 2006-04-15 / Clin. Cancer Res. 2006 Apr;12(8):2555-62Combined action of virus injection and local tumor irradiation on tumor growth in mice
/in International Publications, Newcastle Disease Virus /von 2006-03-01 / Coll Antropol 2006 Mar;30(1):185-9A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
/in International Publications, Newcastle Disease Virus /von 2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67Virus-based therapies for colon cancer
/in International Publications, Newcastle Disease Virus /von 2005-12-01 / Expert Opin Biol Ther 2005 Dec;5(12):1627-33Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2005-10-28 / Mol. Ther. 2006 Jan;13(1):221-8Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
/in International Publications, Newcastle Disease Virus /von 2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-84[Study of Newcastle disease virus killing hepatocellular carcinoma cells in vitro]
/in International Publications, Newcastle Disease Virus /von 2005-06-01 / Zhonghua Gan Zang Bing Za Zhi 2005 Jun;13(6):467-8[Induction of apoptosis in human hepatoma cell line SMMC7721 by Newcastle disease virus HN gene]
/in International Publications, Newcastle Disease Virus /von 2005-05-01 / Zhonghua Zhong Liu Za Zhi 2005 May;27(5):279-82
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
- Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
- Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy